|
|
1180 Avenue of the Americas, Suite 1920
New York, NY 10036 USA
phone:646 214 0700
fax:646 214 0711
|
|
| Symbol |
ZIOP |
| Exchange |
NASDAQ |
| Founded |
0 |
| Employees |
|
|
|
| www.ziopharm.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Small molecule cancer drugs |
|
| Management |
| Jonathan Lewis, M.D., Ph.D., Chief Executive Officer and Chief Medical Officer; Dick Bagley, President and Chief Operating Officer, Director and Treasurer; Barbara Wallner, Ph.D., Chief Technology Officer; Bob Morgan, J.D., Senior Vice President, Regulatory Affairs, Quality, and Clinical Development; Steve Bloom, Vice President, Business Development |
| |
|
|
|
|
|
|
|
| Keywords |
| diverse portfolio, palifosfamide, sarcoma, lymphoma, ovarian, testicular |
|
|
|
| Description |
|
ZIOPHARM Oncology is a biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of small molecule cancer drugs. The Company is currently focused on three clinical programs. Zymafos TM (palifosfamide, ZIO-201) is a novel molecule that is the functional active metabolite of ifosfamide, a standard of care for treating sarcoma, lymphoma, ovarian, testicular and other cancers. Zybulin TM (indibulin, ZIO-301) is a novel, oral tubulin binding agent that targets both mitosis and cancer cell migration. Zinapar TM (darinaparsin, ZIO-101) is a novel organic arsenic being developed for the treatment of various hematologic and solid cancers. |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members